Neuphoria Enters All-Share Merger with Scancell; Combined Company to Focus on Immuno-Oncology
NEUP sits 17% above its 52-week low of $3.19 on elevated volume (41× avg).
Summary
Neuphoria Therapeutics will merge with Scancell Holdings in an all-share deal, with Neuphoria stockholders receiving Scancell ADSs and contingent value rights. The combined company will advance Scancell's cancer immunotherapy pipeline, funded by a concurrent $38.6M PIPE and UK offerings.
Key Events · M&A and Partnerships · NEUP
-
Definitive Merger Agreement Signed
Neuphoria entered an all-share merger agreement with Scancell Holdings on July 23, 2026. Neuphoria stockholders will receive Scancell ADSs at an exchange ratio of 37.77199 and one contingent value right (CVR) per share, representing ~11.1% of the combined company.
-
Concurrent PIPE Financing
Scancell secured commitments for a $38.6 million PIPE at $0.1205 per security, along with a UK placing (~$12M) and retail offer (up to $3M). Proceeds will fund a Phase 3 trial for iSCIB1+ in advanced melanoma.
-
Contingent Value Rights Issued
Each Neuphoria share receives one CVR entitling holders to 100% of net proceeds from Neuphoria's partnered assets (Merck, Pfizer/KAT6) and an Australian R&D tax credit, payable over 15 years. CVRs are non-transferable and not listed.
-
Warrant Amendment with Armistice
Armistice Capital agreed that if the Black Scholes Value of its warrant exceeds $3.5M upon the merger, the excess may be paid in Scancell equity at a 25% premium to the Parent Per Share Price, reducing cash outflow.
Analysis · NEUP · Life Sciences
Neuphoria Therapeutics has signed a definitive all-share merger agreement with Scancell Holdings, creating a combined company focused on Scancell's cancer immunotherapy pipeline. Neuphoria stockholders will receive Scancell ADSs and contingent value rights (CVRs) tied to future payments from Neuphoria's partnered assets. The deal is backed by a concurrent PIPE financing of up to $38.6 million, a UK placing, and a retail offer, aiming to fund a registrational Phase 3 trial for Scancell's lead asset. The merger transforms Neuphoria from a neuropsychiatric-focused company with a failed Phase 3 trial into a stakeholder in a late-stage oncology play, but existing Neuphoria holders face significant dilution, owning only about 11% of the combined entity. The CVRs offer potential upside but are highly uncertain and non-transferable. The transaction is expected to close in late Q4 2026, subject to shareholder and regulatory approvals.
At the time of this filing, NEUP was trading at $3.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $3.19 to $21.40. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.